Skip to content

    Breast Cancer Health Center

    Font Size

    Evista OK for Breast Cancer Prevention

    FDA Approves Osteoporosis Drug Evista for Breast Cancer Prevention in Certain Postmenopausal Women
    WebMD Health News
    Reviewed by Louise Chang, MD

    Sept. 14, 2007 -- The FDA today approved the osteoporosis drug Evista to reduce breast cancer risk in some postmenopausal women.

    Specifically, the FDA approved Evista to lower the risk of invasive breast cancer (the most common form of breast cancer) in two groups of women:

    • Postmenopausal women with osteoporosis
    • Postmenopausal women at high risk for invasive breast cancer

    Evista is only the second drug approved to reduce breast cancer risk (tamoxifen was the first).

    In the U.S., breast cancer is the No. 2 cause of women's cancer deaths (lung cancer is first). Breast cancer accounts for 26% of all cancers among U.S. women.

    "Today's action provides an important new option for women at heightened risk of breast cancer," says Steven Galson, MD, MPH, in an FDA news release.

    But Galson -- who directs the FDA's Center for Drug Evaluation and Research -- cautions that Evista may not be right for all postmenopausal women.

    Weigh Risks, Benefits

    "Because Evista can cause serious side effects, the benefits and risks of taking Evista should be carefully evaluated for each individual woman. Women should talk with their health care provider about whether the drug is right for them," says Galson.

    The FDA notes that Evista can cause serious side effects including blood clots in the legs and lungs and death due to stroke. Women with current or previous blood clots in the legs, lungs, or eyes shouldn't take Evista.

    Other potential side effects include hot flashes, leg cramps, swelling of the legs and feet, flu-like symptoms, joint pain, and sweating, according to the FDA.

    Evista shouldn't be taken by premenopausal women and women who are pregnant or may become pregnant because the drug may harm the fetus. Evista also shouldn't be taken with cholestyramine (a drug used to lower cholesterol levels) or estrogens.

    Evista doesn't completely prevent breast cancer. Breast examinations and mammograms should be done before starting Evista and regularly thereafter.

    About Evista

    Evista belongs to a class of drugs of called selective estrogen receptor modulators (SERMs).

    SERMS may reduce the risk of invasive breast cancer by blocking estrogen receptors in the breast, according to the FDA. Most, but not all, breast cancers are sensitive to estrogen.

    Today on WebMD

    Breast Cancer Overview
    From mammograms to living after treatment.
    Dealing with breast cancer
    Get answers to your questions.
    woman having mammogram
    The 3 latest tips to know.
    woman undergoing breast cancer test
    Most abnormalities aren’t breast cancer.
    Resolved To Quit Smoking
    Breast Cancer Treatments Improving
    Woman getting mammogram
    Screening Tests for Women
    serious woman
    Pink badge on woman chest to support breat cancer
    what is your cancer risk
    breast cancer survivors